Huan Qiu Lao Hu Cai Jing·2026-02-24 03:55Core Viewpoint - Frontier Biotech has signed an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small RNA (siRNA) pipeline products, enhancing its financial structure and accelerating international commercialization efforts [1] Group 1: Licensing Agreement Details - GSK will obtain exclusive global rights for the development, production, and commercialization of two siRNA products, one of which is in the IND stage and the other is a preclinical candidate [1] - Frontier Biotech will receive an upfront payment of $40 million and a near-term milestone payment of $13 million, with potential cumulative milestone payments of up to $950 million based on development, regulatory, and commercialization achievements [1] - Frontier Biotech will conduct Phase I clinical trials for one product in China and support IND research for the other, while GSK will lead global clinical development and commercialization activities [1] Group 2: Financial Performance and Projections - Frontier Biotech's revenue for 2022-2024 is projected to be approximately $8.474 million, $11.4 million, and $12.9 million, respectively, with net losses of $357 million, $329 million, and $201 million due to high R&D expenditures [2] - For 2025, the company expects revenue of $14 million to $14.5 million, representing a year-on-year growth of 8.13% to 11.99%, primarily driven by sales of its innovative HIV drug and other products [2] - The projected R&D expenses for 2025 are estimated to be between $13.8 million and $14.5 million, reflecting a growth of 0.58% to 5.68% as the company focuses on small RNA drug development [2] Group 3: Profitability Outlook - The company anticipates a net loss attributable to shareholders of between $255 million and $290 million for 2025, an increase in losses of approximately $53.6 million to $88.6 million, mainly due to the absence of investment income from the disposal of a subsidiary's equity in 2024 [3]